News

In the event of a recall of a batch, withdrawal of a product from the market or a case of stolen packages, the marketing authorisation holder (MAH) should perform appropriate decommissioning transactions in the EMVS system for the affected markets, reminds the Latvian Medicines Verification Organization (LZVO).

The European Medicines Verification Organisation (EMVO) has launched the EMVS Community Newsletter - edition April 2024. This month, newsletter focusing on Data Quality, featuring insights from EMVO, the Dutch NMVO, Accord Healthcare, and end-user perspectives from the healthcare sector.

LZVO releases newsletter No. 9, where you can find the most important information about events in verification system and our neighbors in Lithuania sharing their experience story.

The performance and operation of the Latvian Medicines Verification System (LZVS) in the first quarter of 2024 have been stable. In the first quarter of 2024, a total of 29 million transactions were carried out in the LZVS, which is a 6% increase compared to the corresponding period in 2023.

While setting up the Lithuanian Medicines Verification Organization (NVVO) came with its challenges in the beginning, ever since its founding back in 2017 we have not swayed from our goal: to ensure the safety of medicines for patients.

During the members' meeting of the Latvian Medicines Verification Organisation (LZVO) on April 10, the association's 2023 annual report was approved. The meeting also discussed current issues and future plans regarding the organization’s activities—such as financial management, financial risks, and their management principles, as well as the maintenance and development of the medicines verification system.